找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: NETWORKING 2004: Networking Technologies, Services, and Protocols; Performance of Computer and Commu; Networking Technolog Nikolas Mitrou,K

[复制链接]
楼主: 弄混
发表于 2025-3-27 00:22:49 | 显示全部楼层
发表于 2025-3-27 01:31:38 | 显示全部楼层
Uday Mohan,Kevin C. Almeroth,Elizabeth M. Belding-Royercellent properties facilitate subsequent interactions of the biomolecules and their interacting partners during the screening process. We envision that the immobilization strategy described here can find useful applications in many other microarray related studies.
发表于 2025-3-27 06:36:54 | 显示全部楼层
发表于 2025-3-27 11:35:30 | 显示全部楼层
发表于 2025-3-27 15:47:56 | 显示全部楼层
发表于 2025-3-27 20:57:49 | 显示全部楼层
Anirban Chakrabarti,Govindarasu Manimaranto as a scoring function. In order to be successful as a virtual screening tool, a docking program must be able to find optimum docking solutions for active molecules in accordance with experiment, it should be able to separate active compounds from inactive ones, and it should use no more than 2–3
发表于 2025-3-28 01:15:17 | 显示全部楼层
Moonseong Kim,Young-Cheol Bang,Hyunseung Chooto as a scoring function. In order to be successful as a virtual screening tool, a docking program must be able to find optimum docking solutions for active molecules in accordance with experiment, it should be able to separate active compounds from inactive ones, and it should use no more than 2–3
发表于 2025-3-28 02:39:12 | 显示全部楼层
Hwangjun Song,Dong Sup Leestic reduction of the tumor bulk within a few hours after administration. Venetoclax was approved by the FDA and EMA in 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), on the basis of a single-arm phase II trial demo
发表于 2025-3-28 06:36:31 | 显示全部楼层
Bernardo A. M. Villela,Otto Carlos M. B. DuarteOlaparib is already approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefits among such patients. It has also shown promising activity in patients with metastatic breast or prostate cancer and a germline
发表于 2025-3-28 10:38:37 | 显示全部楼层
0302-9743 fortunate to attract very high interest among the c- munity, and the conference received 539 submissions from 44 countries in all ?ve continents. These ?gures 978-3-540-21959-0978-3-540-24693-0Series ISSN 0302-9743 Series E-ISSN 1611-3349
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-2 21:11
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表